471 Pharmacokinetics of first and repeated dosing of non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 in advanced cancer patients

• Mei Tang,
• Tianhong Li,
• Karen Kelly,
• Pan Zheng,
• Martin Devenport,
• Hung-Yen Chou,
• Anthony Martinez,
• Stacy Joo

Affiliations

Mei Tang

Department of Rheumatology and Immunology, Second Affiliated Hospital of Soochow University, Suzhou, China

Tianhong Li

Aff98 grid.27860.3b0000000419369684University of California Davis Comprehensive Cancer Center Sacramento CA USA

Karen Kelly

Divison of Hematology and Oncology, Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA

Pan Zheng

Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Martin Devenport

1OncoC4, Inc., Rockville, MD, United States

Hung-Yen Chou

1OncoC4, Inc., Rockville, MD, USA

Anthony Martinez

2UC Davis Comprehensive Cancer Center, Sacramento, CA, USA

Stacy Joo

2UC Davis Comprehensive Cancer Center, Sacramento, CA, USA